Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2021 | PASADENA trial: prasinezumab in early Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, Expert Medical Director, Group Leader, Chair of Medical Directors Fellows at Roche Pharma Research and Early Development (pRED) and Researcher at King’s College London, shares the results from the PASADENA trial (NCT03100149), evaluating the safety and efficacy of prasinezumab in early Parkinson’s disease. The first part of the study did not meet the primary endpoint, change in Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Total score (Parts I + II + III) from baseline to Week 52. However, it reduced the decline in motor function compared to the placebo after one year of treatment, according to the MDS-UPDRS Part III, which is a clinical examination of motor function. This interview took place during the AD/PD™ 2021 conference.


G.Pagano is a full-time employee and shareholder of F. Hoffmann-La Roche Ltd